Actionable Driver Events in Small Cell Lung Cancer

Actionable Driver Events in Small Cell Lung Cancer

Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has alr...

Full description

Bibliographic Details
Main Authors:	Mirian Gutiérrez, Irene Zamora, Michael R. Freeman, Ignacio J. Encío, Mirja Rotinen
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	International Journal of Molecular Sciences
Subjects:	small cell lung cancer heterogeneity targeted therapy inhibitor molecules clinical vulnerability
Online Access:	https://www.mdpi.com/1422-0067/25/1/105

Similar Items

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer
by: Irene Zamora, et al.
Published: (2023-09-01)

Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma
by: Manzar Alam, et al.
Published: (2023-05-01)

Small molecule inhibitors targeting the cancers
by: Gui‐Hong Liu, et al.
Published: (2022-12-01)

Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges
by: Monica A. Kamal, et al.
Published: (2022-08-01)

Oral small molecules for the treatment of atopic dermatitis: a systematic review
by: Pezhman Mobasher, et al.
Published: (2019-08-01)

Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis
by: Jianjing Lin, et al.
Published: (2023-03-01)

Editorial: Recent advances in small molecule-based targeted therapy for breast cancer
by: Thet Thet Htar, et al.
Published: (2023-12-01)

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
by: Jia Zheng, et al.
Published: (2022-04-01)

Research progress on novel molecules and new targets for the control of invasive fungi
by: GUO Xi, LAI Xin-xiu, YANG Mei-yan, LI Qiao-zhen, WANG Si-hang, SONG Zhang-yong
Published: (2021-06-01)

Targeting DDX3 with a small molecule inhibitor for lung cancer therapy
by: Guus M Bol, et al.
Published: (2015-05-01)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
by: Natalia Krzyżanowska, et al.
Published: (2022-10-01)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
by: Yiming Zhao, et al.
Published: (2021-06-01)

Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy
by: Rohan Arora, et al.
Published: (2017-05-01)

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
by: Ying Jin, et al.
Published: (2020-06-01)

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer
by: Vanesa Gregorc, et al.
Published: (2021-04-01)

Small-Molecule PROTACs for Cancer Immunotherapy
by: Zefan Liu, et al.
Published: (2022-08-01)

Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells’ resistance to anti-tumour drugs
by: Meng Chi, et al.
Published: (2023-06-01)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue
by: Shinkichi Takamori, et al.
Published: (2021-08-01)

The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
by: V V Ryazhenov
Published: (2017-01-01)

New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
by: Ramon Andrade de Mello, et al.
Published: (2020-11-01)

Opportunities and challenges of immune checkpoint inhibitors for extensive‐stage small‐cell lung cancer
by: Jing Zhao, et al.
Published: (2022-08-01)

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
by: Abdulaziz B. Hamid, et al.
Published: (2020-04-01)

Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells
by: Yue Yang, et al.
Published: (2022-11-01)

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors
by: Giulia Rotta, et al.
Published: (2024-03-01)

Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
by: Hui Liu, et al.
Published: (2022-04-01)

Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003–2022)
by: Junchen Li, et al.
Published: (2024-01-01)

Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
by: Manuel Hawner, et al.
Published: (2020-12-01)

MEK inhibitors for the treatment of non-small cell lung cancer
by: Jing Han, et al.
Published: (2021-01-01)

Small molecule inhibitors of mammalian glycosylation
by: Karim Almahayni, et al.
Published: (2022-12-01)

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
by: Pottayil G. Sasikumar, et al.
Published: (2022-05-01)

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
by: Hongjian Yang, et al.
Published: (2023-02-01)

Rho GTPase Signaling in Platelet Regulation and Implication for Antiplatelet Therapies
by: Akhila Dandamudi, et al.
Published: (2023-01-01)

Clinical development of targeted and immune based anti-cancer therapies
by: N. A. Seebacher, et al.
Published: (2019-04-01)

Combination therapy: Future directions of immunotherapy in small cell lung cancer
by: Wei Huang, et al.
Published: (2021-01-01)

Editorial: Targeted cancer therapies, from small molecules to antibodies, volume II
by: Chao-Yue Su, et al.
Published: (2023-06-01)

Advances on Driver Mutations of Small Cell Lung Cancer
by: Bing TONG, et al.
Published: (2016-04-01)

Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
by: Shaila A. Shetu, et al.
Published: (2022-03-01)

Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy
by: Fan Yang, et al.
Published: (2022-07-01)

Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell
by: Jiaxing Li, et al.
Published: (2022-06-01)

Microwave Assisted Organic Synthesis (MAOS) of Small Molecules as Potential HIV-1 Integrase Inhibitors
by: Alba Chimirri, et al.
Published: (2011-08-01)